Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Celgene (CELG) Stock Price

News headlines about Celgene (NASDAQ:CELG) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celgene earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.2097422124398 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s rankings:

Celgene (NASDAQ CELG) traded up $0.04 during trading on Wednesday, reaching $93.89. The company had a trading volume of 4,179,650 shares, compared to its average volume of 8,390,000. The firm has a market capitalization of $70,620.00, a price-to-earnings ratio of 17.88, a P/E/G ratio of 0.67 and a beta of 1.49. Celgene has a 52-week low of $88.32 and a 52-week high of $147.17. The company has a debt-to-equity ratio of 2.29, a current ratio of 4.99 and a quick ratio of 4.80.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.78 by $0.09. The firm had revenue of $3.48 billion during the quarter, compared to analyst estimates of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business’s quarterly revenue was up 16.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.61 earnings per share. equities research analysts forecast that Celgene will post 7.68 EPS for the current fiscal year.

Celgene declared that its board has approved a stock buyback plan on Wednesday, February 14th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

CELG has been the topic of a number of research analyst reports. JPMorgan Chase & Co. set a $123.00 target price on Celgene and gave the stock a “buy” rating in a research report on Friday, October 27th. UBS Group decreased their target price on Celgene from $146.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, October 27th. Canaccord Genuity reiterated a “buy” rating and set a $140.00 target price (down from $154.00) on shares of Celgene in a research report on Friday, October 27th. SunTrust Banks decreased their target price on Celgene from $156.00 to $127.00 and set a “buy” rating on the stock in a research report on Friday, October 27th. Finally, Cann reiterated a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $130.25.

In other Celgene news, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $95.99, for a total transaction of $887,907.50. Following the completion of the sale, the director now directly owns 94,801 shares in the company, valued at $9,099,947.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark J. Alles purchased 3,260 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were purchased at an average price of $91.90 per share, with a total value of $299,594.00. Following the completion of the purchase, the insider now directly owns 178,904 shares of the company’s stock, valued at $16,441,277.60. The disclosure for this purchase can be found here. Corporate insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was posted by BBNS and is the sole property of of BBNS. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://baseballnewssource.com/markets/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-celgene-celg-stock-price/1899425.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Insider Buying and Selling by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped


Leave a Reply

 
© 2006-2018 BBNS.